Affimed

Affimed Liabilities

Delisted

The The Liabilities of Affimed (AFMD) as of Nov 22, 2026 is 39.35 M EUR. In the previous year, The Liabilities was 47.60 M EUR — a change of -17.33% (lower).

Liabilities

39.35 MEUR

YoY

-17.33%

Last updated:

In 2023, Affimed's total liabilities amounted to 39.35 M EUR, a -17.33% difference from the 47.60 M EUR total liabilities in the previous year.

The Affimed Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2016
9.99 M EUR
Jan 1, 2017
11.58 M EUR
Jan 1, 2018
76.05 M EUR
Jan 1, 2019
73.69 M EUR
Jan 1, 2020
103.73 M EUR
Jan 1, 2021
89.18 M EUR
Jan 1, 2022
47.60 M EUR
Jan 1, 2023
39.35 M EUR
The Affimed Liabilities history
YEARLiabilitiesYoY
39.35 MEUR-17.33%
47.60 MEUR-46.63%
89.18 MEUR-14.02%
103.73 MEUR+40.76%
73.69 MEUR-3.09%
76.05 MEUR+556.75%
11.58 MEUR+15.93%
9.99 MEUR-17.10%
12.05 MEUR+19.12%
10.11 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Affimed's Liabilities

Affimed's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Affimed's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Affimed's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Affimed's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Affimed’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Affimed stock

The Liabilities of Affimed is 39.35 M EUR in 2023.

The Liabilities of Affimed changed from 47.60 M EUR to 39.35 M EUR, representing a -17.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Affimed since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Affimed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Affimed

All Key Metrics — Affimed